Literature DB >> 1713575

Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells.

S C Mann1, P A Andrews, S B Howell.   

Abstract

We have determined the effect of forskolin, an adenyl cyclase agonist, and 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor, on the accumulation and cytotoxicity of cisplatin (DDP) in 2008 human ovarian carcinoma cells. In DDP-sensitive 2008 cells, forskolin and IBMX caused 2.1-fold and 2.3-fold increases, respectively, in the short-term accumulation of DDP relative to untreated cells. The inactive analogue, 1,9-dideoxyforskolin, decreased DDP accumulation. Forskolin and IBMX also increased accumulation in A2780 cells. Neither forskolin nor IBMX had any effect on DDP accumulation in DDP-resistant 2008 cells. The effects were detectable as early as 1 min and persisted at 60 min. The concentrations for half-maximal stimulation of DDP accumulation were approximately 0.2 microM for forskolin and 0.2 mM for IBMX. Forskolin caused marked increases in cAMP levels in both sensitive and resistant 2008 cells within 1 min, although there were differences in the subsequent time-courses of the response. Both 2008 cell types had identical cAMP-dependent protein kinase (PKA) activity. These results suggest that there is a target downstream of PKA that is an important participant in DDP accumulation, and that this target is defective or missing in DDP-resistant cells. Following a 1-hr exposure to drugs, forskolin and IBMX at concentrations that were by themselves completely non-toxic increased the slopes of the clonogenic survival vs. DDP concentration curves in 2008 cells 1.9-fold and 3.3-fold, respectively. In DDP-resistant 2008 cells, however, forskolin and IBMX increased the slopes only 1.2 and 2.6-fold, respectively. These effects of forskolin and IBMX on DDP cytotoxicity did not directly correlate with the effects on the 1-hr DDP accumulation which suggested that, in addition to modulating DDP accumulation, these agents increase the cytotoxicity of the intracellular platinum. The results indicate that modulation of cAMP levels can have important effects on DDP accumulation and cytotoxicity in 2008 cells and that these effects are significantly diminished in DDP-resistant cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713575     DOI: 10.1002/ijc.2910480613

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Resistance to platinum-based chemotherapy in lung cancer cell lines.

Authors:  Jianli Chen; Nashwa Emara; Charalambos Solomides; Hemant Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-21       Impact factor: 3.333

2.  Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer.

Authors:  K Son; L Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

3.  In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.

Authors:  R D Christen; A P Jekunen; J A Jones; F Thiebaut; D R Shalinsky; S B Howell
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

4.  Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line.

Authors:  E Kimura; R E Enns; F Thiebaut; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.

Authors:  S Isonishi; A P Jekunen; D K Hom; A Eastman; P S Edelstein; F B Thiebaut; R D Christen; S B Howell
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

Review 6.  Signaling and drug sensitivity.

Authors:  R D Christen; S Isonishi; J A Jones; A P Jekunen; D K Hom; R Kröning; D P Gately; F B Thiebaut; G Los; S B Howell
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

7.  Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line.

Authors:  R Jamshidipour; E B Pinho; D K Hom; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

Authors:  Jianli Chen; Mahesha Adikari; Rajash Pallai; Hemant K Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-28       Impact factor: 3.333

9.  Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.

Authors:  H Parekh; H Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells.

Authors:  P Naredi; D D Heath; R E Enns; S B Howell
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.